1,075
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Synthesis and evaluation of in vitro antiviral activity of novel phenoxy acetic acid derivatives

, , , &
Pages 876-882 | Received 05 Apr 2008, Accepted 09 Aug 2008, Published online: 01 Jun 2009
 

Abstract

Several substituted phenoxy acetic acid derived pyrazolines were synthesized by the reaction between 2-{4-[3-(2,4-dihydroxyphenyl)-3-oxo-1-propenyl]-2-methoxyphenoxy} acetic acid and substituted acid hydrazides and were tested for their in vitro cytotoxicity and antiviral activity. None of the compounds showed any specific antiviral activity [50% antivirally effective concentration (EC50) ≥ 5-fold lower than minimum cytotoxic concentration]. The most cytotoxic of the series was 2-{4-[3-(2,4-dihydroxyphenyl)-1-(2-hydroxybenzoyl-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetic acid (3j), with a minimum cytotoxic concentration of 0.16 μg/mL in human embryonic lung (HEL) cells.

Acknowledgements

The authors thank Mrs. Leentje Persoons (Rega Institute for Medical Research) for excellent technical assistance with the antiviral assays and Dr. Ashraf Ali (Research Scientist, Chemical Research Division, Ranbaxy Laboratories, Gurgaon, India) for valuable help and suggestions.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.